Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Phase 2 trial of polatuzumab vedotin, rituximab and dose attenuated CHP in patients 75 years and older with large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

PRPatrick M. ReaganABAndrea BaranCCCarla Casulo

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows improvement in progression-free survival in older patients with large B-cell lymphoma, indicating potential benefits of chemoimmunotherapy.

Key Points

  • To evaluate the efficacy and safety of adding polatuzumab vedotin to dose attenuated chemoimmunotherapy in older patients with large B-cell lymphoma.
  • Enrolled patients aged 75 years and older with large B-cell lymphoma not candidate for standard R-CHOP.
  • Received six cycles of pola 1.8 mg/kg plus R-miniCHP with assessment of geriatric vulnerability.
  • Measured primary endpoint of 2-year progression-free survival and secondary endpoints including overall survival and adverse events.
  • Median PFS was 3.1 years with estimated 2-year PFS of 55%.
  • Fifty-four percent of participants were classified as vulnerable according to VES-13.
  • Achieved a complete response rate of 78.1% among evaluable patients, with overall response rate of 90%.

Cite This Study

Reagan et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d64bhttps://doi.org/10.1182/blood-2025-1918
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R- CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: A real- world study2025
  2. 2Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) therapy in diffuse large B-cell lymphoma in patients aged 80 years or older: a real-world study2025 · 5 citations
  3. 3Efficacy and safety of polatuzumab vedotin–based regimens in newly diagnosed diffuse large B-cell lymphoma: A single-center retrospective study2025
  4. 4Patient characteristics and treatment outcomes with Pola-R-CHP: A real-world study of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) in the United States (US)2025 · 2 citations
  5. 5Real-world outcomes of polatuzumab, rituximab, and lenalidomide in frail pts with diffuse large B-cell lymphoma.2026